Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Späth GF[au]:

Search results

Items: 1 to 50 of 66

1.
2.

Leishmania donovani 90 kD Heat Shock Protein - Impact of Phosphosites on Parasite Fitness, Infectivity and Casein Kinase Affinity.

Hombach-Barrigah A, Bartsch K, Smirlis D, Rosenqvist H, MacDonald A, Dingli F, Loew D, Späth GF, Rachidi N, Wiese M, Clos J.

Sci Rep. 2019 Mar 25;9(1):5074. doi: 10.1038/s41598-019-41640-0.

3.

Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

Lamotte S, Aulner N, Späth GF, Prina E.

Sci Rep. 2019 Jan 24;9(1):438. doi: 10.1038/s41598-018-36944-6. Erratum in: Sci Rep. 2019 Jul 9;9(1):10148.

4.

Drug Discovery for Kinetoplastid Diseases: Future Directions.

Rao SPS, Barrett MP, Dranoff G, Faraday CJ, Gimpelewicz CR, Hailu A, Jones CL, Kelly JM, Lazdins-Helds JK, Mäser P, Mengel J, Mottram JC, Mowbray CE, Sacks DL, Scott P, Späth GF, Tarleton RL, Spector JM, Diagana TT.

ACS Infect Dis. 2019 Feb 8;5(2):152-157. doi: 10.1021/acsinfecdis.8b00298. Epub 2018 Dec 13.

5.

Leishmania Genome Dynamics during Environmental Adaptation Reveal Strain-Specific Differences in Gene Copy Number Variation, Karyotype Instability, and Telomeric Amplification.

Bussotti G, Gouzelou E, Côrtes Boité M, Kherachi I, Harrat Z, Eddaikra N, Mottram JC, Antoniou M, Christodoulou V, Bali A, Guerfali FZ, Laouini D, Mukhtar M, Dumetz F, Dujardin JC, Smirlis D, Lechat P, Pescher P, El Hamouchi A, Lemrani M, Chicharro C, Llanes-Acevedo IP, Botana L, Cruz I, Moreno J, Jeddi F, Aoun K, Bouratbine A, Cupolillo E, Späth GF.

MBio. 2018 Nov 6;9(6). pii: e01399-18. doi: 10.1128/mBio.01399-18.

6.

Reverse Epidemiology: An Experimental Framework to Drive Leishmania Biomarker Discovery in situ by Functional Genetic Screening Using Relevant Animal Models.

Piel L, Pescher P, Späth GF.

Front Cell Infect Microbiol. 2018 Sep 19;8:325. doi: 10.3389/fcimb.2018.00325. eCollection 2018. Review.

7.

Stage-specific expression of the proline-alanine transporter in the human pathogen Leishmania.

Liburkin-Dan T, Schlisselberg D, Fischer-Weinberger R, Pescher P, Inbar E, Ephros M, Rentsch D, Späth GF, Zilberstein D.

Mol Biochem Parasitol. 2018 Jun;222:1-5. doi: 10.1016/j.molbiopara.2018.04.002. Epub 2018 Apr 12.

8.

Characterisation of Casein Kinase 1.1 in Leishmania donovani Using the CRISPR Cas9 Toolkit.

Martel D, Beneke T, Gluenz E, Späth GF, Rachidi N.

Biomed Res Int. 2017;2017:4635605. doi: 10.1155/2017/4635605. Epub 2017 Nov 29.

9.

Haplotype selection as an adaptive mechanism in the protozoan pathogen Leishmania donovani.

Prieto Barja P, Pescher P, Bussotti G, Dumetz F, Imamura H, Kedra D, Domagalska M, Chaumeau V, Himmelbauer H, Pages M, Sterkers Y, Dujardin JC, Notredame C, Späth GF.

Nat Ecol Evol. 2017 Dec;1(12):1961-1969. doi: 10.1038/s41559-017-0361-x. Epub 2017 Nov 6.

10.

The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.

Lamotte S, Späth GF, Rachidi N, Prina E.

PLoS Negl Trop Dis. 2017 Jun 8;11(6):e0005480. doi: 10.1371/journal.pntd.0005480. eCollection 2017 Jun. Review.

11.

Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression.

Dumetz F, Imamura H, Sanders M, Seblova V, Myskova J, Pescher P, Vanaerschot M, Meehan CJ, Cuypers B, De Muylder G, Späth GF, Bussotti G, Vermeesch JR, Berriman M, Cotton JA, Volf P, Dujardin JC, Domagalska MA.

MBio. 2017 May 23;8(3). pii: e00599-17. doi: 10.1128/mBio.00599-17.

12.

Old World cutaneous leishmaniasis challenges in Morocco, Algeria, Tunisia and Iran (MATI): a collaborative attempt to combat the disease.

Bahrami F, Späth GF, Rafati S.

Expert Rev Vaccines. 2017 May;16(5):415-417. doi: 10.1080/14760584.2017.1311792. Epub 2017 Apr 10.

PMID:
28359176
13.

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.

Chua MJ, Arnold MS, Xu W, Lancelot J, Lamotte S, Späth GF, Prina E, Pierce RJ, Fairlie DP, Skinner-Adams TS, Andrews KT.

Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):42-50. doi: 10.1016/j.ijpddr.2016.12.005. Epub 2016 Dec 23.

14.

Phenotypic Characterization of a Leishmania donovani Cyclophilin 40 Null Mutant.

Yau WL, Lambertz U, Colineau L, Pescher P, MacDonald A, Zander D, Retzlaff S, Eick J, Reiner NE, Clos J, Späth GF.

J Eukaryot Microbiol. 2016 Nov;63(6):823-833. doi: 10.1111/jeu.12329. Epub 2016 Jun 16.

PMID:
27216143
15.

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.

Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N.

Eur J Med Chem. 2017 Jan 5;125:696-709. doi: 10.1016/j.ejmech.2016.09.064. Epub 2016 Sep 22.

PMID:
27721154
16.

Species- and Strain-Specific Adaptation of the HSP70 Super Family in Pathogenic Trypanosomatids.

Drini S, Criscuolo A, Lechat P, Imamura H, Skalický T, Rachidi N, Lukeš J, Dujardin JC, Späth GF.

Genome Biol Evol. 2016 Jul 2;8(6):1980-95. doi: 10.1093/gbe/evw140.

17.

Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in Leishmania.

Späth GF, Clos J.

Mol Microbiol. 2016 Jun;100(6):923-7. doi: 10.1111/mmi.13374. Epub 2016 Apr 20.

18.

Cross reactivity of S. aureus to murine cytokine assays: A source of discrepancy.

Javed N, Xue G, Lu A, Xing Y, Iwakura Y, Xiao H, Lecoeur H, Späth GF, Meng G.

Cytokine. 2016 May;81:101-8. doi: 10.1016/j.cyto.2016.03.007. Epub 2016 Mar 12.

PMID:
26978550
19.

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2822-33. doi: 10.1128/AAC.00021-16. Print 2016 May.

20.

Implication of different domains of the Leishmania major metacaspase in cell death and autophagy.

Casanova M, Gonzalez IJ, Sprissler C, Zalila H, Dacher M, Basmaciyan L, Späth GF, Azas N, Fasel N.

Cell Death Dis. 2015 Oct 22;6:e1933. doi: 10.1038/cddis.2015.288.

21.

Phosphoproteomic analysis of wild-type and antimony-resistant Leishmania braziliensis lines by 2D-DIGE technology.

Moreira Dde S, Pescher P, Laurent C, Lenormand P, Späth GF, Murta SM.

Proteomics. 2015 Sep;15(17):2999-3019. doi: 10.1002/pmic.201400611. Epub 2015 Jun 17.

PMID:
25959087
22.

A touch of Zen: post-translational regulation of the Leishmania stress response.

Späth GF, Drini S, Rachidi N.

Cell Microbiol. 2015 May;17(5):632-8. doi: 10.1111/cmi.12440. Epub 2015 Apr 8. Review.

23.

Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process.

Forestier CL, Späth GF, Prina E, Dasari S.

Microb Pathog. 2015 Nov;88:103-8. doi: 10.1016/j.micpath.2014.10.012. Epub 2014 Oct 31. Review.

PMID:
25448129
24.

Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability.

Cayla M, Rachidi N, Leclercq O, Schmidt-Arras D, Rosenqvist H, Wiese M, Späth GF.

PLoS Pathog. 2014 Sep 18;10(9):e1004347. doi: 10.1371/journal.ppat.1004347. eCollection 2014 Sep.

25.

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, Prina E, Cayla M, Descoteaux A, Späth GF.

Mol Microbiol. 2014 Jul;93(1):146-66. doi: 10.1111/mmi.12648. Epub 2014 Jun 3.

26.

The Leishmania donovani chaperone cyclophilin 40 is essential for intracellular infection independent of its stage-specific phosphorylation status.

Yau WL, Pescher P, MacDonald A, Hem S, Zander D, Retzlaff S, Blisnick T, Rotureau B, Rosenqvist H, Wiese M, Bastin P, Clos J, Späth GF.

Mol Microbiol. 2014 Jul;93(1):80-97. doi: 10.1111/mmi.12639. Epub 2014 May 23.

27.

Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying phosphorylation trends.

Tsigankov P, Gherardini PF, Helmer-Citterich M, Späth GF, Myler PJ, Zilberstein D.

Mol Cell Proteomics. 2014 Jul;13(7):1787-99. doi: 10.1074/mcp.M114.037705. Epub 2014 Apr 16.

28.

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF.

Antimicrob Agents Chemother. 2014;58(3):1501-15. doi: 10.1128/AAC.02022-13. Epub 2013 Dec 23.

29.

[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes].

Louzir H, Aoun K, Späth GF, Laouini D, Prina E, Victoir K, Bouratbine A.

Med Sci (Paris). 2013 Dec;29(12):1151-60. doi: 10.1051/medsci/20132912020. Epub 2013 Dec 20. French.

30.

Photoconvertible pathogen labeling reveals nitric oxide control of Leishmania major infection in vivo via dampening of parasite metabolism.

Müller AJ, Aeschlimann S, Olekhnovitch R, Dacher M, Späth GF, Bousso P.

Cell Host Microbe. 2013 Oct 16;14(4):460-7. doi: 10.1016/j.chom.2013.09.008.

31.

Phosphoproteomic analysis of differentiating Leishmania parasites reveals a unique stage-specific phosphorylation motif.

Tsigankov P, Gherardini PF, Helmer-Citterich M, Späth GF, Zilberstein D.

J Proteome Res. 2013 Jul 5;12(7):3405-12. doi: 10.1021/pr4002492. Epub 2013 Jun 11.

PMID:
23688256
32.

Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound.

Leclercq O, Bartho K, Duelsner E, von Kleist L, Gherardini PF, Palmeri A, Helmer-Citterich M, Baumgart S, Späth GF.

J Proteomics. 2013 Jun 28;86:97-104. doi: 10.1016/j.jprot.2013.05.002. Epub 2013 May 16.

PMID:
23684787
33.

High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.

Aulner N, Danckaert A, Rouault-Hardoin E, Desrivot J, Helynck O, Commere PH, Munier-Lehmann H, Späth GF, Shorte SL, Milon G, Prina E.

PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2154. doi: 10.1371/journal.pntd.0002154. Print 2013.

34.

Apoptotic marker expression in the absence of cell death in staurosporine-treated Leishmania donovani.

Foucher AL, Rachidi N, Gharbi S, Blisnick T, Bastin P, Pemberton IK, Späth GF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1252-61. doi: 10.1128/AAC.01983-12. Epub 2012 Dec 21.

35.

The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms.

Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A.

Structure. 2012 Oct 10;20(10):1649-60. doi: 10.1016/j.str.2012.07.005. Epub 2012 Aug 9.

36.

CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation.

Müller AJ, Filipe-Santos O, Eberl G, Aebischer T, Späth GF, Bousso P.

Immunity. 2012 Jul 27;37(1):147-57. doi: 10.1016/j.immuni.2012.05.015. Epub 2012 Jun 21.

37.

PhosTryp: a phosphorylation site predictor specific for parasitic protozoa of the family trypanosomatidae.

Palmeri A, Gherardini PF, Tsigankov P, Ausiello G, Späth GF, Zilberstein D, Helmer-Citterich M.

BMC Genomics. 2011 Dec 19;12:614. doi: 10.1186/1471-2164-12-614.

38.

Imaging host cell-Leishmania interaction dynamics implicates parasite motility, lysosome recruitment, and host cell wounding in the infection process.

Forestier CL, Machu C, Loussert C, Pescher P, Späth GF.

Cell Host Microbe. 2011 Apr 21;9(4):319-30. doi: 10.1016/j.chom.2011.03.011.

39.

Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation.

Pescher P, Blisnick T, Bastin P, Späth GF.

Cell Microbiol. 2011 Jul;13(7):978-91. doi: 10.1111/j.1462-5822.2011.01593.x. Epub 2011 Apr 26.

PMID:
21501362
40.

Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani.

Schmidt-Arras D, Leclercq O, Gherardini PF, Helmer-Citterich M, Faigle W, Loew D, Späth GF.

J Proteomics. 2011 Aug 24;74(9):1644-51. doi: 10.1016/j.jprot.2011.03.024. Epub 2011 Mar 26.

PMID:
21443974
41.

Identification of Leishmania-specific protein phosphorylation sites by LC-ESI-MS/MS and comparative genomics analyses.

Hem S, Gherardini PF, Osorio y Fortéa J, Hourdel V, Morales MA, Watanabe R, Pescher P, Kuzyk MA, Smith D, Borchers CH, Zilberstein D, Helmer-Citterich M, Namane A, Späth GF.

Proteomics. 2010 Nov;10(21):3868-83. doi: 10.1002/pmic.201000305.

PMID:
20960452
42.

Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

Yau WL, Blisnick T, Taly JF, Helmer-Citterich M, Schiene-Fischer C, Leclercq O, Li J, Schmidt-Arras D, Morales MA, Notredame C, Romo D, Bastin P, Späth GF.

PLoS Negl Trop Dis. 2010 Jun 29;4(6):e729. doi: 10.1371/journal.pntd.0000729.

43.

Probing the dynamic nature of signalling pathways by IMAC and SELDI-tof MS.

Foucher AL, Späth GF, Pemberton IK.

Arch Physiol Biochem. 2010 Oct-Dec;116(4-5):163-73. doi: 10.3109/13813455.2010.495129. Epub 2010 Jun 30.

PMID:
20590411
44.

Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.

Dujardin JC, González-Pacanowska D, Croft SL, Olesen OF, Späth GF.

Trends Parasitol. 2010 Aug;26(8):395-403. doi: 10.1016/j.pt.2010.04.012. Epub 2010 Jun 9. Review.

PMID:
20538522
45.

Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage.

Morales MA, Watanabe R, Dacher M, Chafey P, Osorio y Fortéa J, Scott DA, Beverley SM, Ommen G, Clos J, Hem S, Lenormand P, Rousselle JC, Namane A, Späth GF.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8381-6. doi: 10.1073/pnas.0914768107. Epub 2010 Apr 19.

46.

Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage.

Morales MA, Pescher P, Späth GF.

Eukaryot Cell. 2010 Jan;9(1):22-30. doi: 10.1128/EC.00196-09. Epub 2009 Oct 2.

47.

A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection.

Filipe-Santos O, Pescher P, Breart B, Lippuner C, Aebischer T, Glaichenhaus N, Späth GF, Bousso P.

Cell Host Microbe. 2009 Jul 23;6(1):23-33. doi: 10.1016/j.chom.2009.04.014.

48.

A novel role for Stat1 in phagosome acidification and natural host resistance to intracellular infection by Leishmania major.

Späth GF, Schlesinger P, Schreiber R, Beverley SM.

PLoS Pathog. 2009 Apr;5(4):e1000381. doi: 10.1371/journal.ppat.1000381. Epub 2009 Apr 17.

49.

Inflammation recapitulates the ontogeny of lymphoid stromal cells.

Peduto L, Dulauroy S, Lochner M, Späth GF, Morales MA, Cumano A, Eberl G.

J Immunol. 2009 May 1;182(9):5789-99. doi: 10.4049/jimmunol.0803974.

50.

The flagellum-mitogen-activated protein kinase connection in Trypanosomatids: a key sensory role in parasite signalling and development?

Rotureau B, Morales MA, Bastin P, Späth GF.

Cell Microbiol. 2009 May;11(5):710-8. doi: 10.1111/j.1462-5822.2009.01295.x. Epub 2009 Feb 4. Review.

Supplemental Content

Loading ...
Support Center